PT  - JOURNAL ARTICLE
AU  - ELISABETH I. HEATH
AU  - LANCE K. HEILBRUN
AU  - DARYN SMITH
AU  - WILLIAM M. SCHOPPERLE
AU  - YAWEN JU
AU  - SUSAN BOLTON
AU  - QURATULAIN AHMED
AU  - WAEL A. SAKR
TI  - Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer
AID  - 10.21873/anticanres.12994
DP  - 2018 Nov 01
TA  - Anticancer Research
PG  - 6361--6366
VI  - 38
IP  - 11
4099  - http://ar.iiarjournals.org/content/38/11/6361.short
4100  - http://ar.iiarjournals.org/content/38/11/6361.full
SO  - Anticancer Res2018 Nov 01; 38
AB  - Background/Aim: Podocalyxin, a member of the CD34 family of cell surface sialomucins, is overexpressed in human embryonal carcinoma cell lines, as well as in several cancer types, and is associated with poor prognosis. Podocalyxin variants are associated with an increased risk and aggressiveness of prostate cancer. Herein podocalyxin protein expression in prostate cancer was characterized. Materials and Methods: Expression of podocalyxin as well as of TRA-1-60 and TRA-1-81 antigens was assessed immunohistochemically in 84 radical prostatectomy specimens and in adjacent normal tissues. Results: Podocalyxin expression and H-scores were considerably higher in prostate tumors compared to normal tissues. High TRA-1-60 and TRA-1-81 staining was detected, however, in a much smaller percentage of prostate tumors, while their expression and H-scores were low in normal tissues. Similar trends for all three proteins were observed in prostatic intraepithelial neoplasia. Conclusion: Overexpression of podocalyxin in prostate cancer renders the protein a putative immunohistochemical marker of prostate cancer that may contribute to stratification of patients for optimal treatment.